C2i Genomics Announces Successful Evaluation of Whole Genome-Based Residual Disease Test Across Multiple Solid Cancer Models; Company Will Collaborate with AstraZeneca to Explore the C2i Minimal Residual Disease (MRD) Test for Clinical Research & Drug Development

On January 5, 2023, C2i Genomics, a cancer intelligence company, announced an extension of a collaboration with AstraZeneca (LSE/STO/Nasdaq: AZN), a global science-led biopharmaceutical company. The two companies have collaborated to evaluate the potential of whole-genome minimal residual disease (MRD) testing across solid cancers, with the goal of enhancing oncology treatment and supporting clinical trial recruitment and monitoring. C2i genomics has completed AstraZeneca’s BeyondBio Innovation Hub’s program for Israeli start-ups. Using artificially generated samples to reproduce varying levels of circulating tumor DNA (ctDNA) expected to be found in tumors, this collaboration provided early evidence that the C2i assay can sensitively detect ctDNA (down to 0.002% allelic frequency). Building on this work, AstraZeneca will further evaluate and validate the C2i Genomics platform across a panel of patient-derived samples using their in-house sequencing capabilities and expertise. (Note: C2i stands for “command control and intelligence”)

Login Or Register To Read Full Story